Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Exudative Age-Related Macular Degeneration
-
Amir Ghorbanihaghjo
,
Alireza Javadzadeh
,
Nadereh Rashtchizadeh
,
Rana Sorkhabi
,
Hasan Khalili
,
Babak Rahimi-Ardabili
Abstract
Calcification and inflammation are among the important cases of exudative age-related macular degeneration (E-ARMD). The aim of the present study was to elucidate if there is any relationship between serum Osteoprotegerin (OPG), soluble receptor activator of nuclear factor-kappa B ligand (RANK-ligand) and E-ARMD. In a cross-sectional study, we compared 45 E-ARMD patients with 45 matched controls. Diagnosis was confirmed by fluorescein angiography. Serum samples were analyzed for OPG, RANK-ligand, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglyceride (TG). The levels of OPG and RANK-ligand were measured by ELISA methods. The mean age was 72.0±11.5 years in the E-ARMD group and 68.2±8.9 years in the control group (p=0.09). The level of serum OPG was 132.10±75.49 pg/ml in the E-ARMD group and 94.88±61.65 pg/ml in the control subjects. E-ARMD patients had significantly high levels of OPG (p=0.012), as well as significantly high levels of LDL-C and TC (p=0.001 and p=0.005, respectively). We could not find any significant difference in RANK-ligand, HDL-C, or TG between two study groups (p>0.05). To the best of our knowledge, this is the first study investigating the levels of OPG in E-ARMD patients. The present study showed that E-ARMD patients had high levels of serum OPG. It may act as a protective factor for E-ARMD or only as a secondary phenomenon of different processes of E-ARMD. Further prospective studies would be necessary for prognostic and predictive significance of OPG in patients affected by E-ARMD.
Lau LI, Liu CJ, Wei YH. Increase of 8-hydroxy-2’- deoxyguanosine in aqueous humor of patients with exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51(11):5486-90.
Totan Y, Yağci R, Bardak Y, et al. Oxidative macromolecular damage in age-related macular degeneration. Curr Eye Res 2009;34(12):1089-93.
Lommatzsch A, Hermans P, Müller KD, et al. Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunohistochemical analysis of AMD associated with basal deposits. Graefes Arch Clin Exp Ophthalmol 2008;246(6):803-10.
Funk M, Karl D, Georgopoulos M, et al. Neovascular agerelated macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116(12):2393-9.
Kikuchi M, Nakamura M, Ishikawa K, et al. Elevated Creactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular agerelated macular degeneration. Ophthalmology 2007;114(9):1722-7.
Dong L, Qu Y, Jiang H, et al. Correlation of complement factor H gene polymorphisms with exudative age-related macular degeneration in a Chinese cohort. Neurosci Lett 2011;488(3):283-7.
Chu J, Zhou CC, Lu N, et al. Genetic variants in three genes and smoking show strong associations with susceptibility to exudative age-related macular degeneration in a Chinese population. Chin Med J (Engl) 2008;121(24):2525-33.
Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114(12):2174-8.
Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106(10):1192-4.
Zauli G, Pandolfi A, Gonelli A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003;92(7):732-40.
Secchiero P, Corallini F, di Iasio MG, et al. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005;105(9):3413-9.
Anand DV, Lahiri A, Lim E, et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47(9):1850-7.
Avignon A, Sultan A, Piot C, et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005;28(9):2176-80.
Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patientswith acute coronary syndromes. J Am Coll Cardiol 2008;51(6):627-33.
Niessner A, Hohensinner PJ, Rychli K, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009;30(7):789-96.
Secchiero P, Corallini F, Beltrami AP, et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010;210(1):274-7.
Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276(23):20659-72.
Geusens PP, Landewé RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54(6):1772-7.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685-95.
Hofbauer LC, Gori F, Riggs BL, et al. Stimulation ofosteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanism of glucocorticoid-induced osteoporosis. Endocrinology 1999;140(10):4382-9.
Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets 2009;13(6):641-51.
Donoso LA, Kim D, Frost A, et al. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006;51(2):137-52.
Javadzadeh A, Ghorbanihaghjo A, Bahreini E, et al. Plasma oxidized LDL and thiol-containing molecules in,patients with exudative age-related macular degeneration. Mol Vis 2010;16(1):2578-84.
Nowak M, Swietochowska E, Marek B, et al. Changes in lipid metabolism in women with age-related macular degeneration. Clin Exp Med 2005;4(4):183-7.
Hogg RE, Woodside JV, Gilchrist SE, et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008;115(6):1046-52.e2.
Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145(3):527-38.
Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 2008;13(1):135-47.
Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosisinducing ligand, and receptor activator of nuclear factor kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004;89(8):4104-12.
Olesen P, Nguyen K, Wogensen L, Ledet T, et al. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am J Physiol Heart Circ Physiol 2007;292(2):H1058-64.
Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa Bdependent survival factor for endothelial cells. J Biol Chem 2000;275(28):20959-62.
Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 2004;15(6):2834-41.
Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109(18):2175-80.
Rhee EJ, Lee WY, Kim SY, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 2005;108(3):237-43.
Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin related aortic valve calcification. J Mol Cell Cardiol 2004;36(1):57-66.
Lieb W, Gona P, Larson MG, et al. Biomarkers of the osteoprotegerin pathway:clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30(9):1849-54.
Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204(2):321-9.
Mogelvang R, Pedersen SH, Flyvbjerg A, et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis
| Files | ||
| Issue | Vol 52, No 4 (2014) | |
| Section | Articles | |
| Keywords | ||
| Osteoprotegerin Ligands Nuclear Factor-kappa B Macular Degeneration | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
